A detailed history of Group One Trading, L.P. transactions in Zai Lab LTD stock. As of the latest transaction made, Group One Trading, L.P. holds 4,084 shares of ZLAB stock, worth $109,124. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,084
Previous 2,937 39.05%
Holding current value
$109,124
Previous $50,000 96.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.25 - $24.14 $18,638 - $27,688
1,147 Added 39.05%
4,084 $98,000
Q2 2024

Aug 14, 2024

BUY
$13.72 - $21.55 $40,295 - $63,292
2,937 New
2,937 $50,000
Q3 2023

Nov 09, 2023

BUY
$22.72 - $31.49 $52,551 - $72,836
2,313 Added 31.3%
9,702 $235,000
Q2 2023

Aug 09, 2023

BUY
$25.3 - $39.67 $74,508 - $116,828
2,945 Added 66.27%
7,389 $204,000
Q1 2023

May 12, 2023

SELL
$30.21 - $48.1 $644,046 - $1.03 Million
-21,319 Reduced 82.75%
4,444 $147,000
Q4 2022

Feb 09, 2023

BUY
$22.28 - $38.71 $548,221 - $952,498
24,606 Added 2126.71%
25,763 $790,000
Q3 2022

Nov 09, 2022

SELL
$34.2 - $51.69 $75,240 - $113,718
-2,200 Reduced 65.53%
1,157 $40,000
Q2 2022

Aug 11, 2022

SELL
$23.14 - $49.68 $272,681 - $585,429
-11,784 Reduced 77.83%
3,357 $116,000
Q1 2022

May 12, 2022

SELL
$27.77 - $64.4 $1.79 Million - $4.15 Million
-64,421 Reduced 80.97%
15,141 $666,000
Q4 2021

Feb 11, 2022

BUY
$54.9 - $105.21 $3.83 Million - $7.33 Million
69,681 Added 705.2%
79,562 $5 Million
Q3 2021

Nov 12, 2021

BUY
$105.0 - $178.37 $1.04 Million - $1.76 Million
9,881 New
9,881 $1.04 Million
Q2 2021

Aug 10, 2021

SELL
$125.11 - $180.0 $52,045 - $74,880
-416 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$126.27 - $191.71 $52,528 - $79,751
416 New
416 $56,000

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.62B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.